News from the European Society of Cardiology Congress,
25-29 August, Munich, Germany
More insights from the FOURIER Trial
Greater clinical benefit from evolocumab in patients with metabolic syndrome, with no evidence for an increase in new-onset diabetes mellitus.
Read the report »
Lowering LDL cholesterol with evolocumab confers similar benefit in men and women and across a wide range of ages.
Read the report »
More real-world experience with the use of PCSK9 inhibitors
Accumulating data vindicate the European Society of Cardiology/European Atherosclerosis Society Task Force practical guidance for the use of PCSK9 inhibitors.
Read the report »
Catch-up on the Task Force guidance: Lead author Professor Ulf Landmesser, Charité – Universitätsmedizin Berlin, Germany discusses the guidance in the light of results from FOURIER and ODYSSEY Outcomes.
Watch the video »
| 
